Hoang Ngoc Thao Duong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hoang Ngoc Thao Duong has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Thanh Luan Nguyen
Nam Can Tho University
7 shared publications - Van Hoang Nam Ho
Faculty of Medicine, College of Health Sciences, Nam Can Tho University, Can Tho, Vietnam
5 shared publications - Cong Dang Tran
Faculty of Medicine, College of Health Sciences, Nam Can Tho University, Can Tho, Vietnam
4 shared publications - Phan Ngoc An Huynh
Faculty of Medicine, College of Health Sciences, Nam Can Tho University, Can Tho, Vietnam
4 shared publications - Phuc Tuong Pham
Nam Can Tho University
4 shared publications - Quang Dai Le
Faculty of Medicine, College of Health Sciences, Nam Can Tho University, Can Tho, Vietnam
4 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Elsevier in American Heart Journal Plus: Cardiology Research and Practice
- Vol. 71
Association between early intravenous magnesium sulfate administration and mortality according to systemic immune-inflammation index in critically ill patients with acute heart failure: A retrospective cohort study
- 6 October 2026
- Published by Elsevier in American Heart Journal Plus: Cardiology Research and Practice
- Vol. 71
Open AccessAssociation between early intravenous magnesium sulfate administration and mortality according to systemic immune-inflammation index in critically ill patients with acute heart failure: A retrospective cohort study
- Open Access
- 26 June 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (26) , e49526
Early magnesium administration is associated with lower short-term mortality in sepsis: A propensity score matched cohort study with exploratory stratification by systemic immune–inflammation index
The association between early magnesium sulfate administration and outcomes in sepsis remains incompletely understood, particularly in relation to differences in systemic immune–inflammatory status. In this retrospective cohort study using Medical Information Mart for Intensive Care IV (version 3.1), adult critically ill patients with sepsis were included. Systemic immune–inflammation index (SII) was calculated from platelet, neutrophil, and lymphocyte counts obtained within a peri-intensive care unit window (6 hours before to 24 hours after intensive care unit admission). Early magnesium administration was defined as intravenous magnesium sulfate initiated within the same window. The primary outcome was 30-day all-cause mortality. Propensity score matching was performed to balance baseline characteristics. Associations were examined overall and across SII quartiles using stratified multivariable Cox proportional hazards models, with nonlinear relationships explored using restricted cubic splines. Among 12,087 patients, 6039 received early intravenous magnesium. After propensity score matching, 3396 matched pairs were analyzed. Early magnesium administration was associated with lower 30-day mortality overall (15.8% vs 18.3%, P = .007). In stratified analyses, adjusted hazard ratios were 0.66 (95% confidence interval: 0.51–0.87), 0.65 (0.49–0.85), 0.75 (0.59–0.94), and 0.85 (0.70–1.04) across quartiles 1 to 4. Restricted cubic spline analyses showed descriptive attenuation at higher SII values ( P for interaction = .208), without evidence of a statistically definitive interaction. Early magnesium administration was associated with lower 30-day mortality in critically ill patients with sepsis. Although formal interaction testing did not reach statistical significance, adjusted hazard ratios showed a descriptive gradient of attenuation across increasing SII quartiles, directionally consistent across sensitivity analyses. These findings are hypothesis-generating and require prospective validation.
- 26 June 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (26) , e49526
Open AccessEarly magnesium administration is associated with lower short-term mortality in sepsis: A propensity score matched cohort study with exploratory stratification by systemic immune–inflammation index
The association between early magnesium sulfate administration and outcomes in sepsis remains incompletely understood, particularly in relation to differences in systemic immune–inflammatory status. In this retrospective cohort study using Medical Information Mart for Intensive Care IV (version 3.1), adult critically ill patients with sepsis were included. Systemic immune–inflammation index (SII) was calculated from platelet, neutrophil, and lymphocyte counts obtained within a peri-intensive care unit window (6 hours before to 24 hours after intensive care unit admission). Early magnesium administration was defined as intravenous magnesium sulfate initiated within the same window. The primary outcome was 30-day all-cause mortality. Propensity score matching was performed to balance baseline characteristics. Associations were examined overall and across SII quartiles using stratified multivariable Cox proportional hazards models, with nonlinear relationships explored using restricted cubic splines. Among 12,087 patients, 6039 received early intravenous magnesium. After propensity score matching, 3396 matched pairs were analyzed. Early magnesium administration was associated with lower 30-day mortality overall (15.8% vs 18.3%, P = .007). In stratified analyses, adjusted hazard ratios were 0.66 (95% confidence interval: 0.51–0.87), 0.65 (0.49–0.85), 0.75 (0.59–0.94), and 0.85 (0.70–1.04) across quartiles 1 to 4. Restricted cubic spline analyses showed descriptive attenuation at higher SII values ( P for interaction = .208), without evidence of a statistically definitive interaction. Early magnesium administration was associated with lower 30-day mortality in critically ill patients with sepsis. Although formal interaction testing did not reach statistical significance, adjusted hazard ratios showed a descriptive gradient of attenuation across increasing SII quartiles, directionally consistent across sensitivity analyses. These findings are hypothesis-generating and require prospective validation.
- Open Access
- 12 June 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (24) , e49277
Prognostic performance of the mNUTRIC score for in-hospital mortality in critically Ill patients with severe and critical COVID-19: A retrospective cohort study
The prognostic value of the modified Nutrition Risk in the Critically Ill (mNUTRIC) score in patients with severe and critical Coronavirus disease 2019 (COVID-19) remains insufficiently defined. This study aimed to assess the predictive performance of the mNUTRIC score for in-hospital mortality in patients with severe and critical COVID-19 admitted to the intensive care unit. We conducted a retrospective cohort study including 355 critically ill patients with severe and critical COVID-19 admitted to a university-affiliated hospital in Vietnam. The mNUTRIC score was calculated using the first available clinical and laboratory values recorded within the first 24 hours of intensive care unit admission. The primary outcome was in-hospital mortality. Associations between the mNUTRIC score and mortality were assessed using multivariable logistic regression. Predictive performance was evaluated using the area under the receiver operating characteristic curve (AUC). Overall in-hospital mortality was 36.1%. High nutritional risk, defined as an mNUTRIC score ≥5, was identified in 29.6% of patients. In multivariable analysis, the mNUTRIC score remained independently associated with in-hospital mortality (adjusted odds ratio 1.58, 95% confidence interval 1.24–2.02; P < .001). The mNUTRIC score demonstrated moderate discriminative performance for predicting in-hospital mortality, with an AUC of 0.750 (95% confidence interval 0.698–0.803; P < .001). At the optimal cutoff value of ≥4.5, the sensitivity and specificity for predicting in-hospital mortality were 54.7% and 84.6%, respectively. In critically ill patients with severe and critical COVID-19, the mNUTRIC score was associated with in-hospital mortality and demonstrated moderate prognostic performance. Given the retrospective design, these findings should be interpreted with caution and warrant further prospective validation.
- 12 June 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (24) , e49277
Open AccessPrognostic performance of the mNUTRIC score for in-hospital mortality in critically Ill patients with severe and critical COVID-19: A retrospective cohort study
The prognostic value of the modified Nutrition Risk in the Critically Ill (mNUTRIC) score in patients with severe and critical Coronavirus disease 2019 (COVID-19) remains insufficiently defined. This study aimed to assess the predictive performance of the mNUTRIC score for in-hospital mortality in patients with severe and critical COVID-19 admitted to the intensive care unit. We conducted a retrospective cohort study including 355 critically ill patients with severe and critical COVID-19 admitted to a university-affiliated hospital in Vietnam. The mNUTRIC score was calculated using the first available clinical and laboratory values recorded within the first 24 hours of intensive care unit admission. The primary outcome was in-hospital mortality. Associations between the mNUTRIC score and mortality were assessed using multivariable logistic regression. Predictive performance was evaluated using the area under the receiver operating characteristic curve (AUC). Overall in-hospital mortality was 36.1%. High nutritional risk, defined as an mNUTRIC score ≥5, was identified in 29.6% of patients. In multivariable analysis, the mNUTRIC score remained independently associated with in-hospital mortality (adjusted odds ratio 1.58, 95% confidence interval 1.24–2.02; P < .001). The mNUTRIC score demonstrated moderate discriminative performance for predicting in-hospital mortality, with an AUC of 0.750 (95% confidence interval 0.698–0.803; P < .001). At the optimal cutoff value of ≥4.5, the sensitivity and specificity for predicting in-hospital mortality were 54.7% and 84.6%, respectively. In critically ill patients with severe and critical COVID-19, the mNUTRIC score was associated with in-hospital mortality and demonstrated moderate prognostic performance. Given the retrospective design, these findings should be interpreted with caution and warrant further prospective validation.
- 11 May 2026
- Published by SAGE Publications in Journal of Intensive Care Medicine
Early Magnesium Sulfate Administration and Mortality in Critically Ill Patients with Pneumonia: A Retrospective Analysis of the MIMIC-IV Database
Background: Disturbances in magnesium homeostasis and magnesium supplementation are common in critical illness; however, the association between early intravenous magnesium sulfate administration and clinical outcomes in critically ill patients with pneumonia remains unclear. Methods: This retrospective observational cohort study used data from the Medical Information Mart for Intensive Care IV (version 3.1) database and included critically ill patients admitted to the intensive care unit (ICU) with pneumonia. Patients were classified according to early exposure to intravenous magnesium sulfate, defined as administration from 6 h before to 24 h after ICU admission, or no exposure during this period. The primary outcome was 30-day all-cause mortality, with secondary outcomes including 60-day and 90-day mortality. Associations were evaluated using multivariable Cox proportional hazards models, with prespecified subgroup, interaction, and sensitivity analyses, including propensity score matching. Results: Among 9203 eligible patients, 2975 (32.3%) received early intravenous magnesium sulfate. Magnesium sulfate administration was associated with lower 30-day mortality after multivariable adjustment (adjusted hazard ratio [aHR] 0.84; 95% confidence interval [CI] 0.76-0.94; p = .002). Similar associations were observed for 60-day mortality (aHR 0.86; 95% CI 0.78-0.95; p = .002) and 90-day mortality (aHR 0.87; 95% CI 0.80-0.96; p = .004). Subgroup analysis identified a significant interaction for sepsis status (p for interaction = .007). In a propensity score–matched cohort, magnesium sulfate administration remained associated with lower 30-day mortality (aHR 0.85; 95% CI 0.74-0.96; p = .012). Conclusions: In critically ill patients with pneumonia, early intravenous magnesium sulfate administration was associated with lower mortality. These findings are hypothesis-generating and suggest the need for prospective studies to clarify causality and define optimal dosing and duration of magnesium supplementation in this population.
- 11 May 2026
- Published by SAGE Publications in Journal of Intensive Care Medicine
Early Magnesium Sulfate Administration and Mortality in Critically Ill Patients with Pneumonia: A Retrospective Analysis of the MIMIC-IV Database
Background: Disturbances in magnesium homeostasis and magnesium supplementation are common in critical illness; however, the association between early intravenous magnesium sulfate administration and clinical outcomes in critically ill patients with pneumonia remains unclear. Methods: This retrospective observational cohort study used data from the Medical Information Mart for Intensive Care IV (version 3.1) database and included critically ill patients admitted to the intensive care unit (ICU) with pneumonia. Patients were classified according to early exposure to intravenous magnesium sulfate, defined as administration from 6 h before to 24 h after ICU admission, or no exposure during this period. The primary outcome was 30-day all-cause mortality, with secondary outcomes including 60-day and 90-day mortality. Associations were evaluated using multivariable Cox proportional hazards models, with prespecified subgroup, interaction, and sensitivity analyses, including propensity score matching. Results: Among 9203 eligible patients, 2975 (32.3%) received early intravenous magnesium sulfate. Magnesium sulfate administration was associated with lower 30-day mortality after multivariable adjustment (adjusted hazard ratio [aHR] 0.84; 95% confidence interval [CI] 0.76-0.94; p = .002). Similar associations were observed for 60-day mortality (aHR 0.86; 95% CI 0.78-0.95; p = .002) and 90-day mortality (aHR 0.87; 95% CI 0.80-0.96; p = .004). Subgroup analysis identified a significant interaction for sepsis status (p for interaction = .007). In a propensity score–matched cohort, magnesium sulfate administration remained associated with lower 30-day mortality (aHR 0.85; 95% CI 0.74-0.96; p = .012). Conclusions: In critically ill patients with pneumonia, early intravenous magnesium sulfate administration was associated with lower mortality. These findings are hypothesis-generating and suggest the need for prospective studies to clarify causality and define optimal dosing and duration of magnesium supplementation in this population.
- Open Access
- 10 November 2025
- Published by Springer Nature in Critical Care
- Vol. 29 (1) , 1-3
Rethinking hypomagnesemia: diagnostic thresholds and metabolic implications in critical illness
- 10 November 2025
- Published by Springer Nature in Critical Care
- Vol. 29 (1) , 1-3
Open AccessRethinking hypomagnesemia: diagnostic thresholds and metabolic implications in critical illness
- Open Access
- 5 October 2025
- Published by Springer Nature in Pneumonia
- Vol. 17 (1) , 1-5
Corticosteroids in non-viral acute respiratory distress syndrome (ARDS): recommendations outpace evidence – a concise review
The 2024 global redefinition of acute respiratory distress syndrome (ARDS) broadens diagnostic criteria to include patients on non-invasive respiratory support. While this inclusivity enhances early recognition, it also introduces heterogeneity in disease severity, inflammatory burden, and treatment responsiveness–complicating the use of corticosteroids. Although recent guidelines recommend corticosteroids for moderate-to-severe ARDS, they fall short of specifying optimal timing, dosing, and patient selection. The DEXA-ARDS trial showed that high-dose dexamethasone reduced mortality in moderate-to-severe ARDS regardless of etiology, but its generalizability to less severe or non-intubated patients remains unclear. Conversely, in severe community-acquired pneumonia (CAP), hydrocortisone regimens used in CAPE-COD and APROCCHSS trials demonstrated mortality benefits, suggesting a particular therapeutic niche for corticosteroids in non-viral, infection-associated ARDS. A recent network meta-analysis suggests that low-dose methylprednisolone may reduce ARDS mortality, though phenotype-specific efficacy is not well defined. Despite these encouraging signals, key questions persist: Which corticosteroid? At what dose? For which ARDS phenotype? As evidence accumulates unevenly across ARDS subtypes, guideline-endorsed recommendations may inadvertently mask the nuances required for individualized therapy. Until precision approaches are better defined, clinicians must balance empirical benefit with thoughtful restraint in applying corticosteroids to non-viral ARDS. This concise review summarizes current evidence, key limitations, and pragmatic phenotype-informed strategies for corticosteroid use in non-viral ARDS.
- 5 October 2025
- Published by Springer Nature in Pneumonia
- Vol. 17 (1) , 1-5
Open AccessCorticosteroids in non-viral acute respiratory distress syndrome (ARDS): recommendations outpace evidence – a concise review
The 2024 global redefinition of acute respiratory distress syndrome (ARDS) broadens diagnostic criteria to include patients on non-invasive respiratory support. While this inclusivity enhances early recognition, it also introduces heterogeneity in disease severity, inflammatory burden, and treatment responsiveness–complicating the use of corticosteroids. Although recent guidelines recommend corticosteroids for moderate-to-severe ARDS, they fall short of specifying optimal timing, dosing, and patient selection. The DEXA-ARDS trial showed that high-dose dexamethasone reduced mortality in moderate-to-severe ARDS regardless of etiology, but its generalizability to less severe or non-intubated patients remains unclear. Conversely, in severe community-acquired pneumonia (CAP), hydrocortisone regimens used in CAPE-COD and APROCCHSS trials demonstrated mortality benefits, suggesting a particular therapeutic niche for corticosteroids in non-viral, infection-associated ARDS. A recent network meta-analysis suggests that low-dose methylprednisolone may reduce ARDS mortality, though phenotype-specific efficacy is not well defined. Despite these encouraging signals, key questions persist: Which corticosteroid? At what dose? For which ARDS phenotype? As evidence accumulates unevenly across ARDS subtypes, guideline-endorsed recommendations may inadvertently mask the nuances required for individualized therapy. Until precision approaches are better defined, clinicians must balance empirical benefit with thoughtful restraint in applying corticosteroids to non-viral ARDS. This concise review summarizes current evidence, key limitations, and pragmatic phenotype-informed strategies for corticosteroid use in non-viral ARDS.